https://svhealthinvestors.com/ 2024-08-16T08:21:35+00:00 1.00 https://svhealthinvestors.com/strategy 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/biotechnology 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/funds/the-dementia-discovery-fund 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/healthcare 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/funds/medtech-convergence-fund 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/people 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/portfolio 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/news 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/contact 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/news/pulse-biosciences-inc-appoints-paul-laviolette-to-its-board-of-directors-paul-laviolette-to-serve-as-co-chairman-alongside-robert-w-duggan-adding-40-years-of-medical-technology-development-operating-and-leadership-expertise 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/news/spineology-announces-25-million-equity-financing-funding-to-aid-in-acceleration-of-commercial-growth-clinical-education-programs-and-product-development-enhancements-for-highly-differentiated-optimesh-implant-portfolio 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/news/montara-therapeutics-closes-8-million-seed-round-led-by-sv-health-investors-dementia-discovery-fund-and-two-bear-capital-to-develop-safer-more-effective-neuroscience-drugs-using-a-novel-brain-only-pharmacology-approach 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/funds/biotech-funds 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/funds/growth-fund 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/privacy-policy 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/terms-of-use 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/the-uk-stewardship-code-statement-of-commitment 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/sv-health-managers-llp-engagement-policy 2024-08-16T08:21:35+00:00 0.80 https://svhealthinvestors.com/people/alex-badamchi 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/laurence-barker 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/jamil-beg 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/jonathan-behr 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/kate-bingham 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/dan-burgess 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/james-costine 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/damian-crowther 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/charles-dunn 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/freya-easton 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/georgina-ewels 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/georgia-frost 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/emily-guadiano 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/david-guyer 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/tim-harris 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/brett-haumann 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/nikki-hecht 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/michael-heneka 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/susan-hill 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/lynne-hughes 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/rachel-jones 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/christian-jung 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/ray-jupp 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/iain-kilty 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/dirk-landgraf 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/gloria-lau 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/tetsu-maruyama 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/hannah-maunder 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/ruth-mckernan 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/jonathan-mott 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/jodie-oneill 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/jane-osbourn 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/kevin-pojasek 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/anne-prener 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/michael-quigley 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/ravi-rao 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/david-reynolds 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/mike-ross 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/darshi-singh 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/lennart-spindler 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/jennifer-stewart 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/james-summers 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/barbara-tate 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/anup-thapa 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/nikola-trbovic 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/neil-weir 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/joanna-wolak 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/huiyuan-zhang 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/bioage-announces-first-patient-dosed-in-the-strides-phase-2-clinical-trial-evaluating-azelaprag-as-a-novel-treatment-for-obesity-in-combination-with-tirzepatide 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/transposon-announces-final-results-from-a-phase-2-study-of-tpn-101-for-the-treatment-of-c9orf72-related-amyotrophic-lateral-sclerosis-and-or-frontotemporal-dementia 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/quell-therapeutics-appoints-experienced-biopharma-leader-luke-beshar-as-independent-chair-of-its-board-of-directors 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/aspire-ftd-phase-1-2-clinical-trial-opens-in-the-u-s-at-the-ohio-state-university-wexner-medical-center 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/biotechnology 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/luca-santarelli 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/rana-al-hallaq 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/niranjan-bose 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/chas-bountra-obe 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/ceri-davies 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/michael-hutton 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/john-lyons 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/alastair-d-reith 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/dominic-walsh 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/charlotte-yeh 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/vice-president-janssen-cilag-uk-disease-area-leader-neurodegeneration 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/susan-kohlhaas 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/harness-therapeutics-appoints-leading-world-experts-in-neurodegenerative-diseases-to-its-scientific-advisory-board-sab 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/amphista-therapeutics-unveils-new-differentiated-mechanism-of-action-for-brd9-degradation-at-2024-protein-degradation-in-focus-symposium 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/transposon-receives-us-fda-fast-track-designation-for-tpn-101-for-progressive-supranuclear-palsy 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/the-dementia-discovery-fund 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/michael-balmuth 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/andrew-cappetta 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/kelly-dekeyser 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/greg-dulgarian 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/brent-faduski 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/tom-flynn 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/eugene-hill 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/vineela-kanagala 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/greg-madden 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/kate-mccabe-2 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/sam-osman 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/tom-patton 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/tom-policelli 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/aj-rossi 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/james-walker 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/onkos-surgical-announces-first-fda-de-novo-approval-of-an-antibacterial-coating-for-tumor-and-revision-orthopaedic-implants 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/miach-orthopaedics-raises-20-million-in-series-b-extension 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/hightop-health-adds-industry-veteran-to-board-of-directors 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/sv-health-investors-partners-with-hit-executives-dave-dyell-and-marc-hirshfield-to-lead-recapitalization-of-innovative-consulting-group 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/healthcare 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/paul-laviolette 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/aaron-sandoski 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/shuji-yamamoto 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/megan-macdonagh 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/ryan-pierce 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/karyn-ragonese 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/edwards-lifesciences-expands-structural-heart-portfolio-with-acquisitions-of-jenavalve-and-endotronix 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/brixton-biosciences-announces-33m-in-series-b-funding-to-advance-novel-technology-for-the-treatment-of-pain 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/perfuze-announces-fda-clearances-for-novel-neurovascular-aspiration-and-access-catheters-for-stroke-treatment 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/perfuze-announces-first-stroke-patient-enrolled-in-the-marrs-pivotal-clinical-trial-for-the-millipede-system 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/vibrato-medical-announces-positive-results-for-early-feasibility-study-of-wearable-non-invasive-therapeutic-ultrasound-to-treat-chronic-limb-threatening-ischemia 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/medtech-convergence-fund 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/rob-butler 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/bruce-cerullo 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/stephen-griggs 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/robin-hoke 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/phil-incarnati 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/stephen-kahane 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/people/pam-simpkins 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/endotronix-receives-fda-premarket-approval-of-the-cordella-pa-sensor-system-for-the-treatment-of-heart-failure 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/merck-signs-3bn-deal-for-kate-bingham-backed-eye-disease-biotech 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/sv-health-investors-created-eyebio-to-be-acquired-by-msd-for-up-to-3-billion 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/nanopath-receives-4-million-in-grants-from-national-institutes-of-health-and-national-science-foundation 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/quralis-to-present-data-that-show-its-splice-switching-asos-restore-unc13a-function-in-als-and-frontotemporal-dementia 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/sv-investment-has-resulted-in-the-approval-of-24-novel-therapeutics 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/sv-health-investors-bolsters-senior-biotech-team-appoints-nikola-trbovic-as-managing-partner-and-hires-jamil-beg-as-partner 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/merck-to-acquire-caraway-therapeutics-inc 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/eyebio-announces-expansion-of-series-a-to-130-million-advances-development-of-restoret-for-retinal-diseases 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/uk-needs-covid-style-push-on-dementia-drugs-says-ex-head-of-vaccine-taskforce 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/steven-james-accomplished-ceo-and-biotech-executive-joins-board-of-directors-of-rondo-therapeutics 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/sitryx-announces-leadership-transition 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/trexbio-announces-collaboration-partner-lilly-has-initiated-a-phase-1-study-of-trb-051-for-autoimmune-and-inflammatory-diseases 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/p2 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/p42 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/biotech-funds 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/growth-fund 2024-08-16T08:21:35+00:00 0.64 https://svhealthinvestors.com/news/biotechnology/p2 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/biotechnology/p21 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/therini-bio-announces-positive-preclinical-data-supporting-the-development-of-thn391-in-neurodegenerative-ocular-diseases 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/cerevance-achieves-first-milestone-in-research-collaboration-with-msd 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/cerevance-adds-47-million-in-series-b-1-extension-to-advance-robust-clinical-pipeline 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/harness-therapeutics-appoints-seasoned-biopharmaceutical-leader-ms-meenu-chhabra-karson-as-board-chair 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/aviadobio-announces-first-patient-treated-in-aspire-ftd-clinical-trial-evaluating-avb-101-for-frontotemporal-dementia-with-grn-mutations 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/ribometrix-presents-first-c-myc-data-validating-rna-targeting-platform-and-demonstrates-synergistic-potential-of-eif4e-program-at-aacr-2024 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p2 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p11 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/hightop-health-launches-unique-outpatient-mental-health-platform 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/sv-health-investors-completes-partnership-with-packaging-compliance-labs 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/sv-health-investors-acquires-robling-medical 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/hps-paymedix-closes-on-25-million-in-new-funding 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/ria-health-secures-18-million-series-a-to-scale-online-alcohol-use-disorder-treatment 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/memorial-hermann-health-system-joins-existing-investors-in-leiters-a-503b-outsourced-pharmaceutical-compounding-industry-leader 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/sv-health-investors-announces-acquisition-of-nordic-consulting-partners-by-accrete-health-partners-a-strategic-holding-company-of-bon-secours-mercy-health 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/healthcare/p2 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/healthcare/p6 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/ai-enabled-senior-care-company-carepredict-scores-29m 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/feinstein-institutes-northwell-use-ultrasound-to-treat-brain-tumors-in-novel-clinical-trial 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/alison-burkland-co-founder-of-mcf-portfolio-company-nanopath-has-been-named-one-of-forbes-30-under-30 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/amogha-tamidety-focuses-on-underserved-field-of-womens-health 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/artemis-health-and-zerigo-health-announce-partnership-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/podimetrics-odimetrics-declares-war-on-diabetic-foot-amputations 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/nanopath-secures-10-million-in-series-a-funding-to-develop-and-commercialize-point-of-care-diagnostics-for-womens-health 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/medtech-convergence-fund/p2 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/medtech-convergence-fund/p3 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/the-sean-m-healey-amg-center-for-als-and-prilenia-therapeutics-announce-first-participant-enrolled-in-nih-sponsored-act-for-als-expanded-access-protocol-for-pridopidine 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/former-sv-portfolio-company-deciphera-acquired-by-ono-pharmaceutical-for-2-4b-after-biotechs-phase-3-win 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/p3 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/autifony-therapeutics-obtains-1-3-million-in-funding-from-innovate-uk-and-the-dementia-discovery-fund-to-explore-novel-approach-to-treatment-of-dementia 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/ddf-acquires-small-molecule-library-and-enters-strategic-partnership-with-aptuit-to-kickstart-dementia-drug-discovery-programmes 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/kate-bingham-receives-bia-lifetime-achievement-award-at-annual-gala-dinner 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/launch-of-dementia-discovery-fund-new-fund-raises-100-million-to-deliver-novel-approaches-to-treatment-of-dementia 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/ddf-invests-in-gen2-neuroscience-ltd 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/sv-appoints-world-renowned-chief-scientific-officer-to-lead-the-new-ddf-investment-team 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/ddf-makes-first-investment-in-alector-llc 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/p41 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/pulmocide-announces-successful-results-from-the-opera-s-study-a-phase-2-safety-study-with-inhaled-opelconazole 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/biotech-funds/p2 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/biotech-funds/p10 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/nordic-named-best-in-klas-for-overall-it-services-recognized-for-its-industry-leading-advisory-services 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/bioventus-completes-the-acquisition-of-misonix 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/growth-fund/p2 2024-08-16T08:21:35+00:00 0.51 https://svhealthinvestors.com/news/prilenia-to-present-latest-research-from-its-pridopidine-programs-for-huntington-disease-and-als-at-aan-2024 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sitryx-nominates-syx-5219-a-novel-oral-and-targeted-pkm2-activator-for-clinical-development-in-atopic-dermatitis 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/biotechnology/p3 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/bicycle-therapeutics-announces-exclusive-strategic-collaboration-with-genentech-to-develop-and-commercialize-bicycle-based-immuno-oncology-therapies-1 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/bicycle-therapeutics-and-cancer-research-uk-to-collaborate-on-development-of-new-bicycle-immuno-oncology-candidate-bt7401 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-listed-8th-in 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-listed-6th-in-forbes-list-of-vcs-making-the-most-investments-in-healthcare-startups 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/bicycle-therapeutics-closes-40-million-52-million-in-series-b-financing-to-advance-clinical-pipeline 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/arsanis-completes-45-5-million-series-d-financing 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/biotechnology/p20 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/cumulus-neuroscience-receives-innovate-uk-small-business-research-initiative-sbri-grant-focused-on-clinical-biomarker-tools-and-technologies-for-dementia 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-launches-its-inaugural-esg-and-impact-report 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/dementia-discovery-fund-look-ahead-2024-is-shaping-up-to-be-another-big-year-in-the-fight-against-dementia 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/uk-dementia-adviser-ruth-mckernan-wants-half-a-million-volunteers-for-clinical-trials 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/cumulus-neuroscience-announces-first-patient-enrolled-in-acceladx-electroencephalogram-eeg-study-for-early-detection-of-alzheimers-dementia 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/nitrase-therapeutics-unveils-pioneering-antibody-candidate-for-parkinsons-disease-based-on-nitration-discovery-in-oral-presentation-at-the-alzheimers-disease-and-parkinsons-disease-ad-pd-conference 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/ribometrix-to-present-new-preclinical-data-from-rna-modulating-small-molecule-programs-targeting-eif4e-and-c-myc-at-the-2024-aacr-annual-meeting 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/on-international-womens-day-sv-venture-partner-ruth-mckernan-reflects-on-some-achievements-of-sv-biotech-portfolio-companies 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/transposon-announces-final-results-from-a-phase-2-study-of-its-line-1-reverse-transcriptase-inhibitor-tpn-101-for-the-treatment-of-progressive-supranuclear-palsy-and-interim-results-from-a-phase-2-study-of-tpn-101-for-the-treatment-of-c9orf72-related 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sudo-biosciences-announces-second-close-of-upsized-series-b-financing-bringing-total-raised-in-round-to-147m 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/amphista-therapeutics-announces-new-data-demonstrating-in-vivo-efficacy-and-cns-activity-of-its-mechanistically-differentiated-targeted-protein-degraders 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/quralis-strengthens-global-presence-with-opening-of-european-headquarters-that-includes-r-d-manufacturing 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p3 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/jlabs-meet-with-dementia-discovery-fund-1 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/ddf-attracts-investment-from-nfl-players-association 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/ddf-invests-in-20-million-in-series-a-funding-of-mitoconix-bio-to-develop-neurodegenerative-disease-therapies 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/dementia-discovery-fund-annual-update 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/ddf-to-invest-5-million-in-cerevance-to-seek-new-treatments-for-dementia 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p10 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/leiters-announces-facility-acquisition-to-increase-capacity-accommodate-growth-and-expand-portfolio 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/centauri-health-solutions-adds-clinical-data-exchange-capabilities-with-acquisition-of-secure-exchange-solutions 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/welsh-carson-anderson-stowe-acquires-majority-stake-in-leiters 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-announces-three-realizations-in-its-growth-equity-portfolio 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/insights-into-svs-focus 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/wellsky-to-acquire-healthify-to-enhance-social-services-care-coordination-across-the-continuum 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/bioventus-and-misonix-announce-definitive-agreement-for-bioventus-to-acquire-misonix 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/veranex-announces-investment-from-summit-partners-to-form-comprehensive-concept-to-commercialization-medtech-services-company 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/evidation-raises-153m-to-scale-virtual-health-capabilities-of-achievement-platform 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/wellspring-capital-management-recapitalizes-healthpro-heritage 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/healthcare/p3 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/healthify-raises-16m-to-integrate-health-and-social-services 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/skyknight-capital-invests-in-home-healthcare-leader-aerocare 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/misonix-inc-completes-acquisition-of-regenerative-medical-company-solsys-medical 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/lilly-evidation-health-and-apple-study-shows-personal-digital-devices-may-help-in-the-identification-of-mild-cognitive-impairment-and-mild-alzheimers-disease-dementia 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/washington-regional-and-urgent-team-family-of-urgent-care-join-forces 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/jet-health-inc-acquires-boise-idaho-based-first-choice-home-health-and-hospice-marks-companys-entry-into-hospice-arena 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/bardy-diagnostics-announces-35-5m-in-series-b-funding-round 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/lilly-and-evidation-health-expand-collaboration-to-analyze-data-from-smartphones-and-connected-sensors 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/schweiger-dermatology-group-named-to-crains-new-york-business-fast-50-list-2018 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/nordic-acquires-the-claro-groups-revenue-cycle-transformation-practice 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/aligned-telehealth-names-dan-castillo-president-and-coo 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/healthcare/p5 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/fda-grants-alpheus-medical-orphan-drug-and-fast-track-designations-for-novel-sonodynamic-therapy-for-brain-cancer 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/podimetrics-secures-45m-for-smartmat-to-prevent-diabetic-amputations-in-high-risk-patients 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/alpheus-medical-announces-formation-of-world-class-scientific-advisory-board-sab-to-support-development-of-novel-treatment-for-brain-cancer 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/neurovascular-company-perfuze-raises-22-5m-25m-series-a-for-a-new-stroke-treament 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/endotronix-announces-fda-approval-for-proactive-hf-pivotal-trial-design-change-to-single-arm-study 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/carepredict-inc-is-mentioned-in-the-wall-street-journal-as-a-top-trend-to-watch-in-ces2022 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/zerigo-health-expands-board-of-directors 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/alpheus-medical-closes-16m-in-series-a-financing-for-novel-glioma-brain-cancer-treatment 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/vibrato-medical-an-innovator-in-the-treatment-of-peripheral-arterial-disease-pad-announced-that-paul-a-laviolette-has-been-appointed-to-its-board-of-directors 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/zerigo-health-raises-43-million-in-series-b-funding-to-drive-adoption-of-the-industrys-only-connected-light-therapy-solution-to-treat-chronic-skin-conditions 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-promotes-greg-madden-to-managing-partner 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/comprehensive-at-home-treatment-and-coaching-solution-for-chronic-skin-conditions-rebrands-as-zerigo-health 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-announces-the-appointment-of-megan-macdonagh 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/clarify-medical-now-approved-as-a-multiplan-participating-provider 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-features-in-heres-the-top-50-most-active-venture-capital-firms-in-boston-1-1-1 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-announces-the-appointment-of-allan-may-and-ryan-pierce-as-venture-partners-to-the-medtech-convergence-fund 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/paul-laviolette-appointed-to-edwards-lifesciences-board-of-directors 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/clarify-medical-appoints-john-e-schellhorn-as-president-and-chief-executive-officer 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-announces-formation-of-the-medtech-convergence-fund 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/ebt-secures-usd-10m-series-a 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/clarify-medical-closes-18m-series-a-round-to-commercialize-its-connected-home-phototherapy-system-in-the-u-s-clarify-medical 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/p4 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/ddf-attracts-50-million-investment-from-bill-gates 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/ddf-notes-major-collaboration-between-portfolio-company-alector-and-abbvie 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/adimab-provides-mid-year-update-on-2017-partnership-activity 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-closes-on-new-fund-focused-on-creating-and-growing-companies-that-advance-science-and-transform-healthcare 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-life-sciences-changes-name-to-sv-health-investors-to-better-reflect-the-firms-longstanding-strategy-and-focus 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/p40 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/prilenia-plans-to-submit-marketing-authorization-application-maa-in-the-eu-for-pridopidine-in-huntingtons-disease 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/bioage-raises-170m-as-obesity-spotlight-shifts-to-oral-options-muscle-preservers 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/eyebio-targets-registrational-trial-after-early-success-of-wnt-agonist-in-retinal-diseases 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/eyebio-announces-positive-visual-anatomic-and-safety-data-from-first-in-human-ph1b-2a-amarone-trial-of-restoret-at-macula-society-annual-meeting 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/bioage-announces-170-million-oversubscribed-series-d-financing-to-accelerate-development-of-obesity-and-metabolic-disease-therapeutics 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/biotech-funds/p3 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/xilio-therapeutics-to-present-data-on-tumor-selective-immunotherapies-at-the-2020-society-for-immunotherapy-of-cancer-sitc-annual-meeting 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/alchemab-partners-with-amii-to-accelerate-the-development-of-novel-therapeutics-to-cure-disease 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-welcomes-six-new-venture-partners-to-the-biotech-team 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-announces-launch-of-biotech-portfolio-company-cellinta-and-the-companys-appointment-of-dr-soraya-bekkali-as-ceo 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/sv-health-investors-announces-the-appointment-of-alex-badamchi-zadeh-phd-strengthening-their-transatlantic-biotech-team 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/xilio-therapeutics-appoints-paul-j-clancy-to-its-board-of-directors 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/british-patient-capital-commits-65m-to-sv-health-investors-to-invest-in-life-changing-biotechnology-companies 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/alchemab-therapeutics-among-three-companies-that-comprise-the-inaugural-funding-cycle-of-illumina-accelerator-cambridge-uk 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/xilio-therapeutics-appoints-daniel-s-lynch-as-chair-of-board-of-directors 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/xilio-therapeutics-appoints-martin-h-huber-m-d-as-chief-medical-officer-to-lead-xtx201-tumor-selective-il-2-and-xtx101-tumor-selective-actla-4-into-the-clinic-while-xilio-continues-to-advance-its-tumor-selective-cytokine-pipeline 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/biotech-funds/p9 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/the-annual-healthcare-growth-update 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/health-payment-systems-inc-welcomes-sv-health-investors-as-new-lead-investor 2024-08-16T08:21:35+00:00 0.41 https://svhealthinvestors.com/news/biotechnology/p4 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sutro-biopharma-to-present-updated-clinical-data-for-its-stro-002-antibody-drug-conjugate-at-the-aacr-virtual-annual-meeting-on-april-27-2020 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/bicycle-therapeutics-announces-pipeline-progress-update 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sv-health-investors-announces-licensing-and-research-collaboration-between-sitryx-and-lilly-to-discover-and-develop-new-immunometabolic-medicines 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sutrovax-announces-110m-series-d-financing-to-advance-broadest-spectrum-pneumococcal-vaccine-candidates-to-prevent-pneumonia 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/avrobio-reports-fourth-quarter-and-fiscal-year-2019-financial-results-and-provides-business-update 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sutro-biopharma-announces-extension-of-first-cytokine-derivative-research-program-under-collaboration-with-merck 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/bicycle-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-corporate-updates 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/avrobio-receives-orphan-drug-designation-from-u-s-fda-for-avr-rd-04-for-cystinosis 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/deciphera-pharmaceuticals-inc-announces-fourth-quarter-and-full-year-2019-financial-results 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sv-health-investors-joins-xilio-therapeutics-100-5-million-series-b-financing 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/evelo-biosciences-announces-biomarker-data-showing-edp1815-is-an-orally-delivered-dual-cytokine-inhibitor-for-inflammatory-diseases 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/akrevia-therapeutics-rebrands-as-xilio-therapeutics-and-announces-100-5-million-series-b-financing 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/biotechnology/p19 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/harness-therapeutics-secures-additional-4-million-funding-to-pursue-physiological-upregulation-approach-to-treat-neurodegenerative-diseases 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/dementia-discovery-fund-announces-the-acquisition-of-caraway-therapeutics-by-merck 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/transposon-announces-interim-results-from-a-phase-2-study-of-tpn-101-for-the-treatment-of-progressive-supranuclear-palsy-to-be-presented-at-the-ad-pd-2024-international-conference-on-alzheimers-and-parkinsons-diseases 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/cerevance-doses-first-patient-in-ascend-phase-2-clinical-study-of-cvn424-a-first-in-class-non-dopaminergic-therapy-for-the-treatment-of-parkinsons-disease 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/aviadobio-announces-fda-ind-clearance-and-fast-track-designation-for-avb-101-for-the-treatment-of-frontotemporal-dementia-with-progranulin-grn-mutations 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/cumulus-neuroscience-to-present-data-at-ctad-2023-annual-meeting 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/aviadobio-announces-initiation-of-phase-1-2-clinical-trial-aspire-ftd-evaluating-avb-101-in-people-with-frontotemporal-dementia-with-grn-mutations 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/astronautx-closes-a-48-million-61-million-series-a-financing-to-create-new-treatments-for-alzheimers-disease 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/uk-biotech-group-raises-48mn-for-alzheimers-research 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/the-guardian-pioneering-a-new-era-for-dementia-care 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/fierce-biotech-names-cerevance-a-fierce-15-biotech-company-of-2023 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p4 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/nitrome-biosciences-raises-38m-series-a-financing-to-advance-therapeutics-targeting-a-novel-group-of-enzymes-involved-in-age-related-diseases 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/evelo-biosciences-appoints-neil-graham-m-d-m-b-b-s-m-p-h-as-chief-development-officer-an-industry-veteran-who-brings-deep-experience-in-drug-development-from-leadership-roles-at-regeneron-and-vertex 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/cerevance-closes-45-million-series-b-financing 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/alector-announces-the-appointment-of-paula-hammond-ph-d-to-the-board-of-directors 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/ddf-notes-the-appointment-of-christian-jung-phd-as-partner 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/ddf-notes-astronautx-secures-6-5-million-financing-with-investment-from-ddf 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/ddf-launches-new-research-accelerator-partnership-with-the-uk-dri 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/bill-gates-announces-new-investment-in-alzheimers-research-to-help-launch-diagnostics-accelerator 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/dementia-discovery-fund-announces-the-appointment-of-angus-grant-phd-as-ceo 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/the-dementia-discovery-fund-raises-350-million 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/ddf-announce-research-collaboration-with-immuneering 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/ddf-welcomes-recent-fda-guidance-which-opens-new-paths-for-alzheimers-treatments 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p9 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/nordic-acquires-bails-associates 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/aerocare-announces-completion-of-acquisition-by-adapthealth 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/chime-names-bruce-cerullo-nordics-chairman-of-the-board-a-healthcare-hero 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/hillrom-announces-planned-acquisition-of-bardy-diagnostics-inc 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/a-united-front-to-improve-health-outcomes-in-northeast-kansas-healthifys-latest-partnership 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/managed-care-organizations-target-social-determinants-in-ohio 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/adapthealth-corp-announces-acquisition-of-national-hme-provider-aerocare-holdings-inc-and-updates-financial-guidance-for-2021 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/centauri-health-solutions-ranked-the-119th-fastest-growing-company-in-north-america-on-deloittes-2020-technology-fast-500 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/centauri-health-solutions-adds-referral-management-and-analytics-capabilities-with-acquisition-of-ivy-ventures-llc 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/saint-thomas-and-urgent-team-partner-to-expand-affordable-health-services-create-new-patient-entry-points 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/healthcare/p4 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/bardy-diagnostics-announces-ce-mark-certification-for-14-day-carnation-ambulatory-monitor-cam-patch-in-europe-and-expansion-of-home-enrollment-program-amidst-covid-19-crisis 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/study-uses-self-reporting-and-wearables-to-track-and-analyze-symptoms-and-impacts-of-covid-19-data-also-shared-with-syndrome-trackers 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/amwell-introduces-new-telehealth-offering-for-physician-practices 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/amwell-strengthens-leadership-team-with-new-hires 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/covid-19-pulse-from-evidation 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/amwell-launches-national-covid-19-telehealth-response-program 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/american-wells-amwell-app-named-top-online-therapy-service-by-wirecutter 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/bardy-diagnostics-announces-commercial-launch-of-the-14-day-carnation-ambulatory-monitor-cam-patch 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/bardy-diagnostics-names-ed-vertatschitsch-as-chief-operating-officer-and-announces-additions-to-the-leadership-team 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/centauri-health-solutions-welcomes-abry-partners-as-new-lead-investor 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/bardy-diagnostics-wins-the-remote-monitoring-in-arrhythmias-digital-health-pitch-session-at-european-society-of-cardiology-congress-2019-and-presents-at-uk-heart-rhythm-congress-2019 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/american-well-acquires-aligned-telehealth-to-expand-behavioral-health-virtual-care 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/p5 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/schweiger-dermatology-group-announces-100-million-investment-from-lnk-partners 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/science-2-startup-symposium-convened-over-230-academic-researchers-venture-capitalists-entrepreneurs-and-pharmaceutical-executives-creating-connections-that-can-advance-scientific-innovation-and-e 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/wsj-health-forum-22-may-2018 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/atlas-venture-f-prime-capital-partners-and-sv-health-investors-to-host-symposium-featuring-therapeutics-startup-ideas-from-worlds-top-academic-research-institutions 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/avrobio-inc-announces-60-million-series-b-financing-to-advance-gene-therapy-pipeline-for-lysosomal-storage-disorders-and-apply-lentiviral-platform-to-other-genetic-diseases 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/bill-gates-interview-cites-ddf-investment 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sv-health-investors-announces-promotions-within-financial-team 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sv-health-investors-promotes-michael-balmuth-to-managing-partner-and-houman-ashrafian-to-partner 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/pionyr-immunotherapeutics-completes-62-million-series-b-financing-to-advance-antibody-based-therapeutics-targeting-the-tumor-microenvironment 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/p39 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/kate-bingham-participates-in-the-times-health-commission-report-summit 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/prilenia-announces-clinical-data-in-support-of-its-plans-to-initiate-global-phase-3-study-in-als 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sv-is-hiring-executive-assistant-venture-capital-growth-equity-firm 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sv-is-hiring-analyst-associate 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/sitryx-announces-collaboration-partner-lilly-has-commenced-a-phase-1-study-of-sit-011-for-chronic-autoimmune-and-inflammatory-diseases 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/boehringer-ingelheim-licenses-multiple-dark-antigens-from-enara-bio-to-develop-off-the-shelf-immunotherapies-for-non-small-cell-lung-cancer-nsclc 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/imbria-reports-positive-topline-results-for-investigational-new-drug-ninerafaxstat-in-patients-with-cardiac-ischemia-and-chronic-stable-angina 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/imbria-reports-positive-topline-results-for-investigational-new-drug-ninerafaxstat-in-patients-with-non-obstructive-hypertrophic-cardiomyopathy 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/biotech-funds/p4 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/mestag-therapeutics-announces-collaboration-with-janssen-focused-on-the-discovery-of-novel-fibroblast-targets-for-the-treatment-of-inflammatory-disease 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/imbria-pharmaceuticals-presents-phase-1-and-preclinical-data-of-imb-1018972-imb-101-an-investigational-cardiac-mitotrope-at-the-american-college-of-cardiology-70th-annual-scientific-session-expo 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/xilio-therapeutics-presents-preclinical-tumor-selective-activity-and-tolerability-data-for-xtx101-at-frontiers-in-cancer-immunotherapy-virtual-symposium 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/therini-bio-secures-17-million-investment-to-advance-fibrin-therapeutic-candidates-towards-the-clinic 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/xilio-therapeutics-appoints-christina-rossi-to-its-board-of-directors 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/catamaran-bio-announces-appointment-of-scott-holmes-as-chief-financial-officer 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/mestag-therapeutics-launches-with-seed-financing-of-11-million-to-develop-therapeutics-targeting-activated-fibroblast-populations-across-inflammatory-disease-and-cancer 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/alchemab-raises-60m-82m-in-series-a-financing-to-advance-novel-platform-for-identifying-disease-modifying-antibody-therapeutics 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/xilio-therapeutics-strengthens-management-team-with-r-d-leadership-appointments 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/alchemab-and-medicines-discovery-catapult-to-develop-landmark-novel-antibody-therapy-for-huntingtons-disease 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/xilio-therapeutics-raises-95-million-in-series-c-financing-to-advance-potent-tumor-selective-immuno-oncology-pipeline 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/catamaran-bio-launches-with-42-million-financing-to-develop-off-the-shelf-car-nk-cell-therapies-to-treat-solid-tumors 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/biotech-funds/p8 2024-08-16T08:21:35+00:00 0.33 https://svhealthinvestors.com/news/biotechnology/p5 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/sutro-biopharma-expands-senior-management-with-the-additions-of-vice-president-of-clinical-development-and-vice-president-of-finance-and-controller 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/fda-grants-full-approval-of-deciphera-pharmaceuticals-qinlock-ripretinib-for-the-treatment-of-fourth-line-gastrointestinal-stromal-tumor 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/avrobio-reports-updated-clinical-data-from-investigational-gene-therapy-programs-for-fabry-disease-and-cystinosis 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/catabasis-pharmaceuticals-reports-first-quarter-2020-financial-results-and-reviews-business-progress 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/bicycle-therapeutics-announces-publication-of-bt5528-mechanism-of-action-in-aacr-journal-molecular-cancer-therapeutics 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/avrobio-and-magenta-therapeutics-announce-collaboration-to-evaluate-targeted-antibody-drug-conjugate-as-a-potential-conditioning-regimen-for-lentiviral-gene-therapies 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/bicycle-therapeutics-announces-first-patient-dosed-in-phase-i-dose-escalation-of-bt5528-in-combination-with-nivolumab 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/avrobio-to-collaborate-with-saladax-biomedical-on-new-high-speed-diagnostic-assay-used-with-busulfan-conditioning-to-enable-widespread-commercialization-of-avrobios-proprietary-platform-globally 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/how-the-uk-life-sciences-industry-is-rising-to-the-challenge-of-covid-19-by-kate-bingham 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/karus-therapeutics-announces-new-data-from-phase-i-cancer-trial-at-aacr 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/sutro-biopharma-announces-encouraging-interim-phase-1-clinical-data-for-a-dose-escalation-study-of-stro-002-antibody-drug-conjugate-in-ovarian-cancer 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/biotechnology/p18 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/a-born-listener-cns-startup-violet-hones-in-on-cellular-cross-talk 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/ddf-unleashing-innovation-a-new-era-for-dementia 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/renowned-neuroscientist-prof-michael-heneka-m-d-joins-the-dementia-discovery-fund-ddf-as-scientific-advisor 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/cumulus-neuroscience-completes-patient-enrollment-for-pivotal-cns-101-early-stage-alzheimers-dementia-validation-trial 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/violet-therapeutics-raises-10-6-million-in-seed-funding-led-by-the-dementia-discovery-fund-through-ddf-2-and-co-led-by-utec-university-of-tokyo-edge-capital-partners-and-mass-general-brigham-ventures-mgbv 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/first-steps-to-treating-dementia-may-lie-in-related-diseases 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/therini-bio-initiates-first-in-human-dosing-in-phase-1-trial-of-thn391-a-fibrin-targeting-therapeutic-candidate-for-alzheimers-disease 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/therini-bio-raises-36m-series-a-financing-to-develop-fibrin-targeted-therapies-for-neurodegenerative-and-retinal-diseases 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/nitrase-therapeutics-presents-preclinical-data-on-the-role-of-enzymatic-nitration-in-oncology-at-the-american-association-for-cancer-research-annual-meeting 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/quralis-announces-first-patient-dosed-with-qrl-201-a-first-in-class-stathmin-2-precision-therapy-for-als 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/als-biotech-quralis-gets-88m-boost-from-four-pharmas-for-pair-of-phi-studies 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/quralis-closes-88-million-series-b-financing-to-advance-precision-medicines-for-neurodegenerative-diseases 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p5 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/amathus-therapeutics-signs-strategic-collaboration-with-merck-to-develop-treatments-for-neurodegenerative-diseases 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/quralis-continues-to-expand-leadership-team-with-two-key-hires 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/ribometrix-announces-collaboration-with-genentech-to-discover-and-develop-rna-targeted-small-molecule-therapeutics 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/caraway-therapeutics-receives-research-grant-from-the-michael-j-fox-foundation-to-further-investigate-the-function-of-the-lysosomal-ion-channel-tmem175-and-gene-variants-linked-to-parkinsons-disease 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/cerevances-cvn058-achieves-primary-endpoint-in-phase-1b-schizophrenia-cognition-study 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/nitrome-biosciences-announces-formation-of-scientific-advisory-board-and-appointment-of-former-abbvie-executive-james-summers-ph-d-to-sab-chairperson 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/quralis-named-as-one-of-fierce-biotechs-2020-fierce-15 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/excellent-news-today-from-our-portfolio-company-cerevance-on-the-expansion-of-its-series-b-financing-round-adding-a-further-20-million-to-the-45-million-announced-in-april 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/quralis-announces-agreement-to-strengthen-als-pipeline 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/astronautx-announces-an-alliance-with-concept-life-sciences-to-accelerate-the-identification-of-novel-therapies-for-alzheimers-disease 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/quralis-raises-42-million-series-a-financing-to-develop-new-therapies-for-amyotrophic-lateral-sclerosis-als 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p8 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/healthify-partners-with-altruista-health-to-help-payors-address-sdoh 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/nordic-acquires-tasman-global 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/schweiger-dermatology-group-acquires-the-new-york-dermatology-practices-of-lillian-graf-m-d-and-leopold-laufer-m-d 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/jet-health-inc-acquires-carrington-hospice-care-inc 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/bardy-diagnostics-announces-appointment-of-kevin-hykes-as-president-and-chief-executive-officer 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/centauri-health-solutions-announces-acquisition-of-hcfs 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/centauri-health-solutions-ranks-no-448-on-the-2020-inc-5000-list-of-americas-fastest-growing-private-companies 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/centauri-health-solutions-adds-new-analytics-capabilities-with-acquisition-of-apprev 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/healthify-partners-with-ride-health-to-provide-non-medical-transportation-services-to-people-in-need 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/evidation-raises-45-million-series-d-hires-cco-to-accelerate-commercial-momentum-and-expand-into-virtual-health 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/collaboration-aims-to-develop-predictive-algorithm-for-symptoms-of-covid-19-by-monitoring-first-responders 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/covid-19s-unprecedented-stress-on-social-services-drives-demand-for-innovative-sdoh-programs 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/p6 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/bicycle-therapeutics-founder-sir-gregory-winter-awarded-nobel-prize-in-chemistry 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/endotronix-raises-45-million-in-series-d-financing-for-the-treatment-of-heart-failure 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/stimwave-names-industry-veterans-paul-laviolette-and-jeffrey-goldberg-to-board-of-directors 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/artios-pharma-announces-84-million-65-million-series-b-financing 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/evidation-health-announces-30m-in-new-funding 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/sutro-biopharma-announced-85-4-million-series-e-round 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/ddf-notes-alector-raises-133-million-in-series-e-financing 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/kate-binghams-the-moment-interview-with-maxinne-mawhinney 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/p38 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/sitryx-announces-partner-lilly-exercises-option-to-sit-011-for-chronic-autoimmune-and-inflammatory-diseases 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/pulmocide-announces-new-clinical-data-confirming-low-potential-for-drug-drug-interactions-with-inhaled-opelconazole 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/mestag-therapeutics-announces-the-appointment-of-expert-advisors-dr-cassandra-choe-juliak-dr-greg-elson-and-samantha-vieira-mba 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/sean-m-healey-amg-center-for-als-awarded-nih-u01-grant-to-support-expanded-access-to-pridopidine-in-collaboration-with-prilenia-therapeutics 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/sitryx-raises-additional-39-million-to-progress-development-of-disease-modifying-therapeutics-for-chronic-autoimmune-and-inflammatory-diseases 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/nimbus-is-back-for-more-raising-210m-to-fuel-pipeline-seven-months-after-4b-takeda-deal 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/nimbus-therapeutics-secures-210m-private-financing-to-advance-next-wave-of-tech-enabled-small-molecule-medicines 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/british-biotech-faces-a-funding-battle-in-race-with-the-us 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/imbria-pharmaceuticals-completes-enrollment-in-the-phase-2-improve-ischemia-clinical-trial-of-ninerafaxstat-in-patients-with-stable-angina 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/ikena-oncology-acquires-pionyr-immunotherapeutics-in-all-stock-transaction 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/mestag-therapeutics-and-vib-enter-into-an-exclusive-partnership-in-oncology 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/eyebio-announces-first-patients-dosed-in-phase-1b-2-trial-of-restoret-in-neovascular-age-related-macular-degeneration-and-diabetic-macular-edema 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/biotech-funds/p5 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/xilio-therapeutics-announces-closing-of-initial-public-offering 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/xilio-therapeutics-announces-pricing-of-initial-public-offering 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/xilio-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-xtx202-for-the-treatment-of-solid-tumors 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/fierce-biotech-names-mestag-therapeutics-as-one-of-its-fierce-15-biotech-companies-of-2021 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/xilio-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-2-clinical-trial-of-xtx101-for-the-treatment-of-patients-with-solid-tumors 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/pulmocides-lead-drug-candidate-opelconazole-pc945-granted-orphan-drug-fast-track-and-qualified-infectious-disease-product-designations-by-us-fda 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/mestag-therapeutics-extends-seed-financing-to-45-million-and-welcomes-new-investors-forbion-gv-formerly-google-ventures-and-northpond-ventures 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/sv-health-investors-signs-the-investing-in-women-code-signifying-its-commitment-to-contribute-to-improving-female-entrepreneurs-access-to-tools-resources-and-finance 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/imbria-pharmaceuticals-announces-enrolment-of-the-first-10-patients-in-improve-dice-an-exploratory-phase-2-study-investigating-the-impact-of-imb-1018972-on-cardiac-energetics-metabolism-and-function-in-patients-with-type-2-diabetes 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/alchemab-therapeutics-appoints-douglas-a-treco-phd-as-chief-executive-officer 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/kate-bingham-is-recognised-in-this-years-queens-birthday-honours-list 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/pulmocide-raises-92-million-in-a-series-c-financing-to-fund-registration-program-for-pc945 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/biotech-funds/p7 2024-08-16T08:21:35+00:00 0.26 https://svhealthinvestors.com/news/biotechnology/p6 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/avrobio-announces-new-patients-dosed-in-gaucher-disease-and-cystinosis-clinical-trials 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/sv-health-investors-notes-gilead-sciences-secures-exclusive-option-to-acquire-pionyr-immunotherapeutics 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/bicycle-therapeutics-appoints-sir-keith-peters-as-chairman-of-its-scientific-advisory-board 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/deciphera-announces-health-canadas-authorization-of-qinlock-ripretinib-for-the-treatment-of-fourth-line-gastrointestinal-stromal-tumor 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/x4-pharmaceuticals-promotes-renato-skerlj-ph-d-to-chief-scientific-officer 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/deciphera-announces-publication-of-the-invictus-pivotal-phase-3-study-of-qinlock-ripretinib-in-the-lancet-oncology 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/ervaxx-rebrands-as-enara-bio-to-reflect-a-broader-emphasis-on-the-discovery-and-development-of-novel-tcr-based-cancer-immunotherapies 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/deciphera-pharmaceuticals-announces-presentations-of-positive-patient-reported-outcomes-results-from-invictus-phase-3-study-of-qinlocktm-ripretinib-in-patients-with-fourth-line-advanced-gist-at-the-asco-2020-virtual-scientific-program 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/biotechnology/p17 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/aviadobio-signs-exclusive-license-agreement-with-neurgain-technologies-for-novel-gene-therapy-spinal-delivery-technology 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/impact-funds-help-fight-dementia-and-antibiotic-resistance 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/cerevance-expands-series-b-financing-with-additional-51-million 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/quralis-announces-first-in-human-dose-in-phase-1-clinical-trial-of-qrl-101-a-first-in-class-kv7-precision-therapy-for-als 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/dementia-discovery-fund-invests-in-amphista-therapeutics-as-it-targets-neurodegenerative-diseases 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/quralis-receives-health-canada-clinical-trial-application-authorization-for-qrl-201-a-first-in-class-stathmin-2-precision-therapy-for-als 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/nitrase-therapeutics-presented-data-on-role-of-novel-nitrases-in-regulating-known-and-important-cancer-targets-at-eortc-nci-aacr-symposium 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/ddf-recognizes-that-the-latest-lecanemab-results-represent-major-progress-in-the-development-of-new-treatments-for-alzheimers-disease 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/cumulus-neuroscience-appoints-digital-health-and-pharmaceutical-executive-aman-bhatti-md-as-chief-executive-officer 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/aviadobio-selected-by-fierce-biotech-as-a-fierce-15-2022-winner 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/alchemab-therapeutics-cracking-the-secrets-of-protective-auto-immunity 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/nitrase-therapeutics-appoints-arun-kashyap-ph-d-to-lead-its-recently-launched-oncology-programs-as-senior-vice-president-of-oncology 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/the-dementia-discovery-fund/p6 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/right-or-wrong-the-aducanumab-decision-could-turbo-boost-investor-interest-in-neurodegeneration 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/the-dementia-discovery-funds-portfolio-company-caraway-therapeutics-establishes-collaboration-with-abbvie-to-develop-small-molecule-therapeutics-targeting-parkinsons-disease-and-other-neurodegenerative-disorders 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/caraway-therapeutics-establishes-collaboration-with-abbvie-to-develop-novel-small-molecule-therapeutics-for-parkinsons-disease-and-other-related-disorders 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/the-dementia-discovery-funds-welcomes-fdas-approval-of-aducanumab-for-alzheimers-disease 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/transine-therapeutics-closes-extended-seed-funding-of-9-1-million-co-led-by-takeda-ventures-inc-and-the-dementia-discovery-fund-to-advance-its-novel-class-of-therapeutic-rnas 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/quralis-boosts-world-class-leadership-team-with-addition-of-three-new-members 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/the-dementia-discovery-fund-appoints-luca-santarelli-m-d-a-proven-neuroscience-leader-as-the-new-chair-of-its-scientific-advisory-board 2024-08-16T08:21:35+00:00 0.21 https://svhealthinvestors.com/news/cumulus-neuroscience-announces-6-million-funding-round-led-by-the-dementia-discovery-fund-and-joined-by-lifearc-and-uk-future-fund 2024-08-16T08:21:35+00:00 0.21